tbuckley/cabot-search huggingface dataset:
Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients
Authors: C da Cunha-Bang, J Simonsen, K Rostgaard, C Geisler, H Hjalgrim, C U Niemann
Journal: Blood Cancer Journal (2016)

The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent decades both combination chemotherapy and immunotherapy have been introduced. To evaluate the effects of this development, we identified all CLL patients registered in the nation-wide Danish Cancer Register between 1978 and 2013. We identified 10 455 CLL patients and 508 995 CLL-free control persons from the general population. Compared with the latter, the relative mortality rate between CLL patients and their controls decreased from 3.4 (95% CI 3.2-3.6) to 1.9 (95% CI 1.7-2.1) for patients diagnosed in 1978-1984 and 2006-2013, respectively. The improved survival corresponded to a decreasing risk of death from malignant hematological diseases, whereas the risk of death from infections was stable during the study period. These population-based data substantiate the improved survival for patients treated with chemo-immunotherapy demonstrated in clinical studies.
Differential Distribution Of Recurrent Gene Mutations In Subsets Of Chronic Lymphocytic Leukemia Patients With Stereotyped B-Cell Receptors: Results From A Multicenter Project Of The European Research Initiative On CLL In A Series Of 2482 Cases
Authors: Panagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, Davide Rossi, Eva Minga, Andreas Agathangelidis, Neus Villamor, Jana Kminkova, Marta Larrayoz, Zadie Davis, Evangelia Stalika, Jitka Malcikova, Antonios M Makris, Larry Mansouri, Lydia Scarfò, Diego Cortese, Karla Plevova, Gunnar Juliusson, Alba Navarro, Julio Delgado, David Oscier, Sarka Pospisilova, Gianluca Gaidano, Elias Campo, Jonathan C Strefford, Chrysoula Belessi, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos
Journal: Blood (2013)
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Authors: Neil M. Iyengar, Ayca Gucalp, Andrew J. Dannenberg, Clifford A. Hudis
Journal: Journal of Clinical Oncology (2016)

Purpose There is growing evidence that inflammation is a central and reversible mechanism through which obesity promotes cancer risk and progression. Methods We review recent findings regarding obesity-associated alterations in the microenvironment and the local and systemic mechanisms through which these changes support tumor growth. Results Locally, hyperadiposity is associated with altered adipose tissue function, adipocyte death, and chronic low-grade inflammation. Most individuals who are obese harbor inflamed adipose tissue, which resembles chronically injured tissue, with immune cell infiltration and remodeling. Within this distinctly altered local environment, several pathophysiologic changes are found that may promote breast and other cancers. Consistently, adipose tissue inflammation is associated with a worse prognosis in patients with breast and tongue cancers. Systemically, the metabolic syndrome, including dyslipidemia and insulin resistance, occurs in the setting of adipose inflammation and operates in concert with local mechanisms to sustain the inflamed microenvironment and promote tumor growth. Importantly, adipose inflammation and its protumor consequences can be found in some individuals who are not considered to be obese or overweight by body mass index. Conclusion The tumor-promoting effects of obesity occur at the local level via adipose inflammation and associated alterations in the microenvironment, as well as systemically via circulating metabolic and inflammatory mediators associated with adipose inflammation. Accurately characterizing the obese state and identifying patients at increased risk for cancer development and progression will likely require more precise assessments than body mass index alone. Biomarkers of adipose tissue inflammation would help to identify high-risk populations. Moreover, adipose inflammation is a reversible process and represents a novel therapeutic target that warrants further study to break the obesity-cancer link.
THU0019 Age-Related Histological Changes in Calcified Cartilage and Subchondral Bone Plate in Complete Human Femoral Heads
Authors: A.W. Nielsen, L.B. Hartlev, R. Klose-Jensen, L.W. Boel, K.K. Keller, E.-M. Hauge
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Age is the most important risk factor for osteoarthritis (OA). However, the pathogenesis of OA is not fully understood, but the subchondral bone plate may be thickened in osteoarthritis. How aging of the joint corresponds to OA changes is poorly elucidated, but preliminary OA alterations may occur in healthy old individuals and progress into symptomatic OA. <h3>Objectives</h3> The objective was to investigate the age-related changes in different tissue compartments of the femoral head hypothesizing that a positive correlation with age would be found for 1) volume of the femoral head; 2) volume and thickness of the subchondral bone plate and calcified cartilage. <h3>Methods</h3> Sixty-one femoral heads from 29 females (median, range) (49, 20–74 years) and 32 males (47, 23–78 years), who had accidently died, were obtained by autopsy from the Institute of Forensic Medicine. Individuals were excluded in case of known bone or joint diseases, or macroscopic cartilage erosions. Design-based stereological methods using systematic uniform random sampling were applied to estimate absolute volume. The femoral heads were randomly rotated around a vertical axis and sawn in 5–8 slabs with a thickness of 7 mm. The slabs were halved and alternating right or left half were embedded in methylmethacrylate from where 7-μm thick sections were cut. The sections were stained with Masson-Goldner trichrome or May-Grünwald toluidine blue. The total absolute volume of the femoral head, calcified cartilage, and the subchondral bone plate were estimated using the Cavalieri estimator. Orthogonal thicknesses of the calcified cartilage and the subchondral bone were measured in uniform randomly selected sampling points and related to the overlying articular cartilage alterations using the OARSI score of histological osteoarthritis. Linear regression was used to test the effect of age on the parameters and t-tests were applied for comparing men and women. <h3>Results</h3> The volume and thickness of the subchondral bone did not correlate with age (Table 1). Calcified cartilage volume and thickness correlated positively with age only in women. The volume of the femoral head correlated positively with age only in men. Women and men did not differ in OARSI-stage or grade. <h3>Conclusions</h3> In complete human femoral heads obtained from a cross-sectional population without macroscopic OA changes, we found no correlation with age for the volume or thickness of the subchondral bone plate. Surprisingly, the two genders differed in the effect of age on volume of the femoral head and volume and thickness of the calcified cartilage even though they had corresponding damage of the articular cartilage. <h3>Disclosure of Interest</h3> None declared
A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).
Authors: Ajay K. Gopal, Joseph G. Rajendran, John M. Pagel, Katherine A. Guthrie, David G. Maloney, Frederick R. Appelbaum, Brenda M. Sandmaier, Rainer F. Storb, Oliver W. Press
Journal: Blood (2006)
AB1030 Effects of Conducting Directly Observed Treatment, Short-Course (DOTS) Strategy and Conferences on Latent Tuberculosis Infection in Rheumatoid Arthritis Patients Undergoing Immunosuppressive Therapy
Authors: M. Tsujimura, T. Fujita, S. Endo, S. Nagai, E. Watanabe
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> As our hospital lacks a pulmonologist, screening for respiratory infections in the treatment of rheumatoid arthritis (RA) is carried out through collaboration with a pulmonary medicine specialist outside of our facility. Patients in whom latent tuberculosis infection (LTBI) is detected by screening are prescribed isoniazid (INH). At the Fuji Public Health Center, which has jurisdiction over our hospital, directly observed treatment, short-course (DOTS) is implemented for all tuberculosis patients, including the LTBI cases registered. In our practice, we have held DOTS conferences (DOTS-C) with the health center regularly since 2013 to ensure proper patient education and thorough patient management. <h3>Objectives</h3> We investigated the status of the respiratory infection screening conducted in our hospital and studied the impact of DOTS-C on treatment outcomes in LTBI and the treatment of RA. <h3>Methods</h3> For 250 patients who underwent screening for respiratory infections between 2010 and 2014, we retrospectively examined data in regard to the items associated with LTBI and RA treatment. <h3>Results</h3> There were 58 patients diagnosed with LTBI and prescribed INH. As of October 31, 2015, immunosuppressive drugs used in the 58 patients were methotrexate in 37 patients at doses of 7.57±2.28 mg/week (mean ± standard deviation), prednisolone in 6 patients at doses of 2.17±0.85 mg/day, and biological preparations in 45 patients. In all cases, the scheduled duration of INH therapy was 270 days. DOTS-C was conducted in 23 patients. The number of patients who completed the entire treatment course was 19 (82.6%) in the DOTS-C group and 11 (31.4%) in the non-DOTS-C group. The number of patients hospitalized and treated for infections and other complications developing during RA treatment was 1 (4.3%) in the DOTS-C group and 8 (22.9%) in the non-DOTS-C group. <h3>Conclusions</h3> In our medical institution, despite not having a pulmonologist, it was possible to complete the entire course of LTBI treatment through collaboration with an associated public health center. Our findings indicate that DOTS-C is useful for achieving both the completion of LTBI treatment and patient education to prevent complications. <h3>Disclosure of Interest</h3> None declared
AB0853 Electroacupuncture Treatment of Meralgia Paraesthetica
Authors: R.E. Alexander
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Meralgia Paraesthetica (MP) (meros = thigh, algos = pain) is an under diagnosed fairly condition caused by entrapment of the lateral femoral cutaneous nerve. Paraesthesiae, numbness or burning typically affect the thigh. I noticed that acupuncture produced a rapid improvement and invited referrals from rheumatology consultants. <h3>Objectives</h3> I had treated several rheumatology patients [1] and decided to do a case series of MP, using a series of tender and traditional Chinese acupuncture points. I found that all patients were tender over GB31 acupuncture point on the affected lateral thigh (7 inches proximal to the popliteal crease). <h3>Methods</h3> A series of 10 patients, including two who had refused surgery (excluding those with significant lumbar spine problems), were treated. Xray/MRI scans were taken if relevant. Acupuncture points used were UB25, GB30, GB34, Ex21 lumbar facet trigger points, GB31+ "Ah chi" tender buttock and Chinese points using an infra-red lamp. Electro-acupuncture (using a dense-disperse mode), was used after the first treatment if significant benefit was not obtained. VAS pain scores were collected weekly from patients prior to treatment by a nurse or receptionist Analgesic intake was recorded. <h3>Results</h3> Without exception patients were tender over GB31 point on the thigh. The pain scores improved for all 10 patients by at least 50% with an average of 3–4 treatments. At follow up (3–36 months), improvement was nearly 100%. They were all able to reduce or stop their medication <h3>Conclusions</h3> A series of 10 patients all improved, including a patient with a 20 year history. Two patients had refused surgery and three were misdiagnosed. The patients had no signs of radiculopathy. Nerve conduction studies were considered to be non feasible. Electroacupuncture appears to be a good treatment for this debilitating condition. A Cochrane review in 2008 found observational studies only, not RCTs [1]. Many patients appear to improve spontaneously but 10–15% may need local steroid/anaesthetic injections. Decompression or resection of the nerve may be necessary [2]. In this series 50% of patients needed surgery. I found one paper only discussing two case reports of the treatment of MP with acupuncture [1]. Acupuncture is a safe non-invasive treatment for this debilitating condition. Tenderness of GB31 acupuncture point on the lateral side of the thigh was consistently present, which may aid diagnosis. <h3>References</h3> Rosemary Alexander, Adrian White "Acupuncture in a Rheumatology Clinic" Acupuncture in Medicine, Dec 2000 VOL 18(2) Khalil N, Nicotra A, Rakowicz W. Treatment for meralgia paraesthetica. CochraneDatabase of Systematic Review 2008, Issue 3.Art.No:CD004159 Ivins GK (August 2000)."Meralgia Paraesthetica The Elusive Diagnosis".Annals of Surgery 232 (2) 281–286. Aigner N et al. Schmertz 1997 Apr 18; 11(2):113–5 <h3>Disclosure of Interest</h3> None declared
mafB Deficient Mouse Results in Impaired Macrophage Differentiation.
Authors: Michito Hamada, Takashi Moriguchi, Naoki Morito, Chuan Zhang, Kazuteru Hasegawa, Keigyou Yoh, Etsushi Kuroda, Tomomasa Yokomizo, James D. Engel, Masayuki Yamamoto, Satoru Takahashi
Journal: Blood (2005)
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Sagar Lonial, Andrzej J Jakubowiak, Sundar Jagannath, Marc S Raab, Thierry Facon, Ravi Vij, Philippe Moreau, Donna E. Reece, Darrell J. White, Lotfi Benboubker, Jeffrey A. Zonder, Jean-Francois Rossi, Claire Tsao, Teresa Parli, Glenn Kroog, Anil K Singhal, Paul G. Richardson
Journal: Blood (2011)
Human Cytomegalovirus: Degranulation Is a Prominent Feature of Functionally Impaired pp65- and IE-1-Specific T-Cells in Patients after Allogeneic Stem Cell Transplantation
Authors: Stephan Fuhrmann, Susanne Ganepola, Lutz Uharek, Eckhard Thiel, Wolf-Dieter Ludwig, Hans-Dieter Volk, Florian Kern
Journal: Blood (2008)
AB1025 Glycemia and Systemic Blood Pressure in Patients Who Receive Corticosteroid Pulse Therapy
Authors: M.U. Martinez Martinez, C. Abud-Mendoza, J. Martínez-Lozano, E.S. Acevedo-Castañeda, D.A. Herrera-van Oostdam
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Supra-pharmacological doses of corticosteroids (pulse therapy) are used in various autoimmune disorders. Methylprednisolone and dexamethasone pulse therapy have demonstrated similar efficacy for some diseases;[1] therefore, differences in their adverse effects can help the selection of any of them. <h3>Objectives</h3> To evaluate changes in glycemia and blood pressure in patients who received pulse therapy with dexamethasone or methylprednisolone. <h3>Methods</h3> We evaluated the charts of patients who received corticosteroid pulse therapy with dexamethasone (200 mg/day) or methylprednisolone (1000 mg/day). We included patients who received at least three days of pulse therapy and who had records of glycemia and blood pressure four times at day. We evaluated the blood pressure and glycemia measurements before the first pulse therapy and the next three-day measurements each six hours. We evaluated through linear mixed models the factors associated with an increase in glycemia or blood pressure (systolic or diastolic) in the program R 3.0.2. For the glycemia analysis we excluded patients with diabetes history and patients having glycemia &gt;180 before the pulse therapy. <h3>Results</h3> We included 117 patients, 83 received pulse therapy with methylprednisolone and 34 with dexamethasone. Multivariate mixed models showed a statistically significant increase in glycemia and blood pressure (systolic and diastolic) from the first measurement after the initial dose of pulse therapy (Figure 1); factors associated with hyperglycemia (adjusted for creatinine levels, sex and units of insulin received) were higher glycemia before the pulse therapy (p=0.0016) and the use of methylprednisolone (p=0.0098). Factors associated with an increase of systolic or diastolic blood pressure were: higher blood pressure before the first pulse therapy (p&lt;0.0001) and higher creatinine levels (p=0.0099 and 0.0031) but not the type of corticosteroid (dexamethasone or methylprednisolone). <h3>Conclusions</h3> Pulse therapy with methylprednisolone showed a higher increase in glycemia than dexamethasone. Susceptible patients to an increase of glycemia are who have initial hyperglycemia; patients susceptible to an increase in blood pressure are who have elevated serum creatinine levels and who have initial hypertension. <h3>References</h3> Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr 2008;75:1057–66. <h3>Disclosure of Interest</h3> None declared
P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153
Authors: David Waterhouse, Leora Horn, Craig Reynolds, David Spigel, Jason Chandler, Tarek Mekhail, Mohamed Mohamed, Ben Creelan, Kenneth B. Blankstein, Petros Nikolinakos, Michael J. Mccleod, Ang Li, Ian M. Waxman, Nivedita Aanur, Shruti Agrawal, Eduardo Richardet
Journal: Journal of Thoracic Oncology (2016)
In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort
Authors: Christopher P. Venner, Nizar J Bahlis, Paola Neri, Irwindeep Sandhu, Peter Duggan, Andrew Belch, Joanne D Hewitt, Linda M. Pilarski, Tatiana Nikitina, Victor H Jimenez-Zepeda
Journal: Blood (2015)
IKZF1 deletions in Pediatric Acute Myeloid Leukemia
Authors: Jasmijn de Rooij, Eva Beuling, C. Michel Zwaan, Askar Obulkasim, André Baruchel, Jan Trka, Dirk Reinhardt, Edwin Sonneveld, Brenda Gibson, Martin Zimmermann, Rob Pieters, Marry van den Heuvel-Eibrink, Maarten Fornerod
Journal: Blood (2014)
Дослідження протеїназо-інгібіторної системи та фібринолітичної активності плазми крові у хворих на гастроезофагеальну рефлюксну хворобу в поєднанні з цукровим діабетом типу 2
Authors: Yu.V. Kohanyuk, O.I. Fediv, L.M. Goncharuk
Journal: GASTROENTEROLOGY (2016)

Мета дослідження: вивчити особливості протеїназо-інгібіторної системи та фібринолітичної активності плазми крові у хворих на гастроезофагеальну рефлюксну хворобу (ГЕРХ) у поєднанні з цукровим діабетом (ЦД) типу 2. Матеріали й методи. У дослідженні брали участь 112 хворих на ГЕРХ віком від 33 до 76 років, які в подальшому розподілялись на групи залежно від форми ГЕРХ. Стан протеїназо-інгібіторної системи крові визначали за методом К.Н. Веремеєнко зі співавт. Стан ферментативного та неферментативного фібринолізу в плазмі крові вивчали за методиками Н. Тіца. Результати дослідження. Під час дослідження протеїназо-інгібіторної системи крові виявлено, що у хворих на ерозивну форму ГЕРХ (ЕГЕРХ) за наявності чи відсутності ЦД типу 2 відбувається вірогідне підвищення інтенсивності лізису дрібнодисперсних, крупнодисперсних білків та колагену порівняно з практично здоровими особами (ПЗО) та хворими на неерозивну форму ГЕРХ (НГЕРХ) (р &lt; 0,05). Зміни концентрації α2-макроглобуліну (α2-МГ) при ГЕРХ були різнонаправленими: зменшення концентрації α2-МГ при ГЕРХ на тлі ЦД типу 2 і, навпаки, збільшення рівня α2-МГ у пацієнтів із ГЕРХ без супровідної патології порівняно з ПЗО. Оцінюючи фібринолітичну активність плазми крові, встановили, що у хворих на ЕГЕРХ, у тому числі поєднану із ЦД типу 2, відзначалося вірогідне зростання фібринолітичної активності плазми крові порівняно з ПЗО (p &lt; 0,05), а в пацієнтів з НГЕРХ та ЦД типу 2 спостерігалась лише тенденція до зростання даних показників (р &gt; 0,05). Новизна. Уперше на підставі вивчення змін протеолітичної й фібринолітичної активності крові та інгібітора протеолізу встановлено нові патогенетичні механізми розвитку та прогресування ГЕРХ у пацієнтів із ЦД типу 2. Практичне значення дослідження. На підставі отриманих даних запропоновано проводити хворим на ГЕРХ, поєднану із ЦД типу 2, повне клінічно-лабораторне обстеження з дослідженням показників протеїназо-інгібіторної та фібринолітичної систем крові для прогнозування розвитку ерозивних уражень стравоходу. Висновок. У хворих на ГЕРХ, поєднану з ЦД типу 2, спостерігається незбалансоване зростання інтенсивності протеолізу за умови зниження експресії його інгібіторів, підвищення фібринолітичної активності плазми крові.
Survival Difference of AML Patients Receiving HLA Matched Sibling Allogeneic Bone Marrow Transplants (ABMT) Correlates with HLA-Cw Ligand Groups for Killer Immunoglobulin-Like Receptors (KIRs).
Authors: Ronald Sobecks, Edward Ball, Lisa Rybicki, Stacey Brown, Matt Kalaycio, Brad Pohlman, Jaroslaw Maciejewski, Brian Bolwell
Journal: Blood (2004)
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Alter the Hematopoietic Niche and Treatment In Healthy Volunteers Results In Mobilization of CD34+ Cells, Hematopoietic Colony Forming Cells, and Endothelial Colony Forming Cells
Authors: Jonathan Hoggatt, Brahmananda Reddy Chitteti, Vani Krishna, Sherif Farag, Magdalena Czader, Mervin C. Yoder, Edward Srour, Louis M. Pelus
Journal: Blood (2010)
Clofarabine in Acute Myeloid Leukemia. the Spanish Experience
Authors: Adolfo de la Fuente, Guillermo Deben, Concha Bethencourt, Silvia Negri, Dolores Vilariño, Sonia Gonzalez, Teresa Olave, Pilar Martinez-Sanchez, Federico Moscardo, Mar Caballero, Rosa Fernandez Martinez, Juan Bergua, Marina Gordillo, Daniel Garcia Belmonte, Angeles Fernandez Fernandez, Silvia Solorzano, Ana Belen Santos, Alejandro Roman, Mar Tormo, Marisa Calabuig, Jl Sastre Moral, Jose Luis Lopez Lorenzo, Pascual Fernández-Abellán, Jose Francisco Tomas
Journal: Blood (2011)
Mixing Study for Evaluation of Abnormal Coagulation Testing
Authors: Sung-Hee Choi, Siayareh Rambally, Yu-Min Shen
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal